BFM
RIGL icon

Boothbay Fund Management’s Rigel Pharmaceuticals RIGL Stock Holding History

Boothbay Fund Management’s Portfolio RIGL Stock Details RIGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q2 		– Sell
-67
Closed -$238K – 872
2018
Q1 		$238K Buy
67
+3
+5% +$120 0.03% 552
2017
Q4 		$248K Buy
+64
New +$2.44K 0.04% 511

Other funds holding RIGL

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VOYA Investment Management
VOYA Investment Management Atlanta, Georgia $96.1B AUM 40.06% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Boothbay Fund Management's RIGL Position: Q3 2022 in Review

Boothbay Fund Management sold out of Rigel Pharmaceuticals (RIGL) in Q3 2022, closing a stake of 9,688 shares — an estimated $109K sold.

Boothbay Fund Management first reported a position in RIGL in Q1 2015 and held it in 18 quarters. The position peaked at $778K in Q1 2022. 138 funds tracked by Wall St. Rank hold RIGL as of Q3 2022.

  • Boothbay Fund Management reported no remaining Rigel Pharmaceuticals position as of Q3 2022 after selling out during the quarter.
  • Boothbay Fund Management sold 9,688 Rigel Pharmaceuticals shares in Q3 2022, an estimated $109K.
  • Boothbay Fund Management first reported a position in Rigel Pharmaceuticals in Q1 2015 and held it in 18 quarters.
  • Boothbay Fund Management's Rigel Pharmaceuticals position peaked at $778K in Q1 2022.
  • 138 funds tracked by Wall St. Rank held Rigel Pharmaceuticals as of Q3 2022.

Based on Boothbay Fund Management's 13F filing for Q3 2022, filed 14 Nov 2022.